How is AOD-9604 dosed and mixed?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds AOD-9604 and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
No label gives a dose; in METAOD005, 300 obese adults took 1, 5, 10, 20 or 30 mg or placebo by mouth once daily for 12 weeks, and in METAOD006, 502 adults with obesity took 0.25, 0.5, or 1 mg once daily, or placebo, for 24 weeks, as Stier and colleagues (2013) and the FDA's 2024 briefing report.12
The guide's example
250 mcg of AOD-9604 from a 5 mg vial mixed with 5 mL is 25 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 5 mL of water | 10 mL of water |
|---|---|---|
| 5 mg | 1 mg/mL: 250 mcg is 25 units, 500 mcg is 50 units | 0.5 mg/mL: 250 mcg is 50 units, 500 mcg is 100 units |
| 10 mg | 2 mg/mL: 250 mcg is 12.5 units, 500 mcg is 25 units | 1 mg/mL: 250 mcg is 25 units, 500 mcg is 50 units |
How a vial mixes and what a dose reads on a syringe
No label or maker's leaflet says which water to use or how much. In the two intravenous trials, METAOD001 and METAOD002 (Stier and colleagues, 2013), the powder was freeze-dried and reconstituted with sterile water for intravenous injection, no volume given.1 The FDA briefing reports a supplier's solubility of 2 mg of acetate per 1 mL of water, and describes marketed vials of 1000 mcg/mL and 600 mcg/ml in 10 mL.2 The vial sizes in the table are arithmetic, not a manufacturer's strengths.
Worked example, as arithmetic only: 250 mcg from a 5 mg vial mixed with 5 mL is 0.25 mL, or 25 units on a U-100 syringe; 250 mcg is not a trial dose, and the forum figure a 2026 review lists is 250–500 µg per day split into 2–3 injections.3
250 mcg of AOD-9604 from a 5 mg vial mixed with 5 mL is 25 units on a U-100 syringe.
What the trials and other records give for dose and schedule
The FDA and TGA records searched show no approved label or regulator-recognised dose. The Australian regulator's decision lists AOD-9604 as a Schedule 4 entry, and the FDA lists it among bulk substances nominated but withdrawn.45 Stier and colleagues (2013) summarised six randomized, double-blind, placebo-controlled trials of about 900 adults, two by injection into a vein and four by mouth.1
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| METAOD001 | 25 to 400 µg/kg or placebo into a vein, dose escalation1 | 15 healthy men1 | Single doses, 7 days apart1 |
| METAOD002 | 25, 50 or 100 µg/kg or placebo into a vein1 | 23 obese men1 | Single doses, Latin square1 |
| METAOD003 | 9, 27 and 54 mg or placebo by mouth in capsules1 | 17 obese men1 | Single doses, 2 weeks apart1 |
| METAOD004 | 9, 27 or 54 mg daily by mouth, or placebo, dose escalation1 | 36 obese men1 | Seven days1 |
| METAOD005 | 1, 5, 10, 20 or 30 mg or placebo by mouth once daily1 | 300 obese adults, 50 per group1 | 12 weeks1 |
| METAOD006 | 0.25, 0.5, or 1 mg once daily by mouth, or placebo, with a supervised diet and exercise program2 | 502 adults with obesity2 | 24 weeks2 |
The FDA briefing found no human information on AOD-9604 given under the skin or on the skin.2 It describes the single-dose oral trial differently: once weekly oral doses of 9, 27 and 54 mg for 4 weeks in 16 men.2 It also lists a 36-man escalation study at 10, 30 or 60 mg for 1 week, route not given.2 For the intravenous trial it gives 23 adults with obesity single doses of 25, 50 or 100 mcg/kg or placebo into a vein, once weekly for 4 weeks.2 Apart from the trials' own dose-escalation designs, such as METAOD001 and the one-week study in 36 men, the label database, registry, PubMed and FDA searches turned up no stepped or cycle plan from a trial or label.12 A 2026 review lists figures from bodybuilding-related forums of 250–500 µg/day under the skin in 2–3 injections, with cycles of 8–12 weeks; these are not trials.3
Storage
The FDA briefing gives -20 °C for AOD-9604 acetate, stable for more than four years.2 It also reports certificates of analysis from one nomination that give a sealed container at 2-8 °C in a fridge for less than 6 months and -20 °C for more than 6 months.2 It cites a supplier's safety data sheet for AOD-9604 free base, kept dry in closed containers: -18 °C for 3 years, 0-7 °C for 1 year and 7-30 °C for half a year.2 Storage or a use-within time after mixing is not stated there.
Frequently asked questions
Is there a registered human trial of AOD-9604?
The FDA briefing says a search of the US trial registry listed no studies on AOD-9604.2
What safety findings are reported for AOD-9604 in humans?
Stier and colleagues (2013), summarising six trials of about 900 adults, report no withdrawal or serious adverse event related to AOD9604 and call its safety and tolerability profile indistinguishable from placebo.1 The FDA briefing lists serious events in people given oral AOD-9604 including diarrhea, chest tightness and various cancers.2
- AOD-9604 calculatorVial, water and dose to syringe units.
- Mixing a vialThe general steps.
- AOD-9604Half-life, trials and status.
- Growth hormone peptidesThe group this compound sits in.
- Tesamorelin dosageLabel doses and mixing.
- CJC-1295 and ipamorelin dosageDoses and mixing.
- HGH dosage in IUUnits for growth hormone.
References
- J Endocrinol Metab. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. 2013. jofem.org
- FDA. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, December 4, 2024. 2024. fda.gov
- Front Endocrinol (Lausanne). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. 2026. pmc.ncbi.nlm.nih.gov
- TGA. Reasons for scheduling delegate's final decisions for the ACMS, March 2015 (18 November 2014 meeting). 2015. tga.gov.au
- FDA. Substances in Compounding that May Present Significant Safety Risks. 2026. fda.gov